In this issue:
Treatment of patients with IgG4-related disease
Pain remission with routine TNF inhibitor treatment for axial SpA
Ixekizumab for axial SpA
Secukinumab vs TNF inhibitors for Takayasu arteritis
Serum complement 3 risk factor for vascular stenosis in Takayasu arteritis
Subcutaneous vs intravenous infliximab in RA
Hypogammaglobulinaemia in ANCA-associated vasculitis after rituximab induction
Cancers and cardiovascular diseases with JAK inhibitors/biologics
Humoral immune response to COVID-19 vaccination after TNF inhibitor
Please login below to download this issue (PDF)